POST-TESTFORCME
Thankyou forparticipating in thisCMEactivity. Inorder toobtain16.0
AMAPRACategory1Credits™
youmust:
1) Read the learningobjectives;
2) Read the articles and study the tables andfigures in this supplement;
3) Register and complete thispost-test online;
4) Complete the application forCME credit and the activity evaluation formonline.
FormoreCME informationvisit
ReleaseDate:
April 7, 2014
ExpirationDate:
April 1, 2015
Time toCompleteActivity:
16.0hours
A11
©TheCanadian Journal ofUrology™: International Supplement, April 2014
1. Whichof the following is thedefinitionof castration resistant prostate cancer (CRPC)?
a. Castrationresistantprostatecancer isdefinedbydiseaseprogressiondespiteandrogendeprivation therapy
and requires evidenceof newmetastases by imaging.
b. Castrationresistantprostatecancer isdefinedasdiseaseprogressiondespiteandrogendeprivation therapy
andmaypresent as either a continuous rise in serumPSA levels, theprogressionof pre-existingdisease,
and/or the appearanceof newmetastases.
c. Castration resistant prostate cancer isdefinedby risingPSAprior to androgendeprivation therapy.
d. Castration resistant prostate cancer isdefinedby three risingPSA’swith a castrate level of testosterone.
2. A 55-year-oldmale presents to you after receiving a diagnosis of prostate cancer. His PSA is 4.6 ng/mL,
Gleason score 3+3=6 in 3 of 12 coreswith 25% involvement of each core. Hementions that he has a strong
familyhistoryof prostate cancer (brother diagnosed at 62 years old, father andgrandfather). He is strongly
considering radiation therapy, but alsowonders about the roleof “hormone treatment” inhis case. Whichof
the following statementsBESTdescribes theutilityof androgendeprivation therapy in thispatient?
a. Androgen deprivation therapy is commonly used asmonotherapy in patients with clinically localized
prostate cancer.
b. Androgendeprivation therapydoes have side effects, but it shouldbe reserved formenwithmetastatic
diseaseonly.
c. Althoughandrogendeprivation therapy isuseful asadjuvant therapy to radiation treatment forprostate
cancer, there is little tonobenefit inmenwith lowgradedisease.
d. Neoadjuvant androgendeprivation therapy is superior to adjuvant therapywhen considering radiation
treatment for prostate cancer.
3. After initiationofdegarelix therapy, castrate levelsof testosteroneareachieved inover90%ofpatientswithin:
a. 24hours.
b. 3days.
c. 7days.
d. 28days.
4. Regardingdegarelix,which statement isTRUE:
a. Degarelix is a competitive antiandrogenpeptide.
b. Degarelix competitivelyblocks theGnRH receptor.
c. This agent causes a surge in serumT for up to 28days after initial administration.
d. Co-administrationof anon-steroidal anti-androgen is recommendedwith the initialdoseofdegarelix.
